Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models.
Mazahreh R, Mason ML, Gosink JJ, Olson DJ, Thurman R, Hale C, Westendorf L, Pires TA, Leiske CI, Carlson M, Nguyen LT, Cochran JH, Okeley NM, Yumul R, Jin S, Stone IJ, Sahetya D, Nesterova A, Allred S, Hensley KM, Hu R, Lawrence R, Lewis TS, Sandall S. Mazahreh R, et al. Among authors: stone ij. Mol Cancer Ther. 2023 Apr 3;22(4):421-434. doi: 10.1158/1535-7163.MCT-22-0401. Mol Cancer Ther. 2023. PMID: 36800443 Free PMC article. Clinical Trial.
Anti-CD30 diabody-drug conjugates with potent antitumor activity.
Kim KM, McDonagh CF, Westendorf L, Brown LL, Sussman D, Feist T, Lyon R, Alley SC, Okeley NM, Zhang X, Thompson MC, Stone I, Gerber HP, Carter PJ. Kim KM, et al. Mol Cancer Ther. 2008 Aug;7(8):2486-97. doi: 10.1158/1535-7163.MCT-08-0388. Mol Cancer Ther. 2008. PMID: 18723494
Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.
Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, Pan L, Cronkite A, Sussman D, Klussman K, Ulrich M, Anderson ME, Stone IJ, Zeng W, Jonas M, Lewis TS, Goswami M, Wang SA, Senter PD, Law CL, Feldman EJ, Benjamin DR. Li F, et al. Among authors: stone ij. Mol Cancer Ther. 2018 Feb;17(2):554-564. doi: 10.1158/1535-7163.MCT-17-0742. Epub 2017 Nov 15. Mol Cancer Ther. 2018. PMID: 29142066
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index.
McDonagh CF, Kim KM, Turcott E, Brown LL, Westendorf L, Feist T, Sussman D, Stone I, Anderson M, Miyamoto J, Lyon R, Alley SC, Gerber HP, Carter PJ. McDonagh CF, et al. Mol Cancer Ther. 2008 Sep;7(9):2913-23. doi: 10.1158/1535-7163.MCT-08-0295. Mol Cancer Ther. 2008. PMID: 18790772 Free article.
Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates.
Burke PJ, Hamilton JZ, Pires TA, Setter JR, Hunter JH, Cochran JH, Waight AB, Gordon KA, Toki BE, Emmerton KK, Zeng W, Stone IJ, Senter PD, Lyon RP, Jeffrey SC. Burke PJ, et al. Among authors: stone ij. Mol Cancer Ther. 2016 May;15(5):938-45. doi: 10.1158/1535-7163.MCT-16-0038. Epub 2016 Mar 4. Mol Cancer Ther. 2016. PMID: 26944920
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.
Gerber HP, Kung-Sutherland M, Stone I, Morris-Tilden C, Miyamoto J, McCormick R, Alley SC, Okeley N, Hayes B, Hernandez-Ilizaliturri FJ, McDonagh CF, Carter PJ, Benjamin D, Grewal IS. Gerber HP, et al. Blood. 2009 Apr 30;113(18):4352-61. doi: 10.1182/blood-2008-09-179143. Epub 2009 Jan 15. Blood. 2009. PMID: 19147785 Free article.
SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.
Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RP, Zeng W, Harrington KH, Klussman K, Westendorf L, Meyer D, Bernstein ID, Senter PD, Benjamin DR, Drachman JG, McEarchern JA. Kung Sutherland MS, et al. Blood. 2013 Aug 22;122(8):1455-63. doi: 10.1182/blood-2013-03-491506. Epub 2013 Jun 14. Blood. 2013. PMID: 23770776 Free article.
20 results